- Home
- THRD
as 11-07-2024 4:00pm EST
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 512.9M | IPO Year: | 2022 |
| Target Price: | $20.33 | AVG Volume (30 days): | 184.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.82 - $16.94 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Third Harmonic Bio Inc. (THRD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Conner Edward R. | THRD | Chief Medical Officer | Oct 28 '24 | Sell | $15.00 | 2,673 | $40,095.00 | 0 | |
| Conner Edward R. | THRD | Chief Medical Officer | Sep 19 '24 | Sell | $15.00 | 4,790 | $71,850.00 | 0 | |
| Person Julie | THRD | CHIEF ADMINISTRATIVE OFFICER | Sep 18 '24 | Sell | $14.14 | 10,000 | $142,726.59 | 0 |
Latest Third Harmonic Bio Inc. News
THRD Breaking Stock News: Dive into THRD Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
GlobeNewswire
21 hours ago
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Argus Research
7 days ago
Daily – Vickers Top Buyers & Sellers for 11/01/2024
Simply Wall St.
2 months ago
Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business
GlobeNewswire
2 months ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
GlobeNewswire
2 months ago
Third Harmonic Bio to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5 months ago
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
Compare THRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THRD Third Harmonic Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.